Citi analysts added Cytokinetics (CYTK) and HII (HII) to the firm’s 2025 North America Focus List while removing IntercontinentalExchange (ICE) and Coca-Cola (KO). The list features Citi’s “differentiated, high conviction, catalyst-driven calls across the region.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYTK:
- Optimistic Buy Rating on Cytokinetics Driven by Promising Aficamten Trial Outcomes
- Biotech Alert: Searches spiking for these stocks today
- Cytokinetics’ Aficamten Poised as Best-in-Class Cardiac Treatment with Favorable Risk-Benefit Profile
- Optimistic Buy Rating for Cytokinetics: Aficamten’s Market Potential Amidst Competition
- Cytokinetics: A Promising Investment with Aficamten’s Competitive Edge in HCM Treatment
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue